The antitumor effect of blocking CTLA-4 with tremelimumab in the treatment of HCV-associated advanced HCC was demonstrated in a phase 2 trial (NCT01008358), involving 21 patients. The gene discussed is CTLA4; the disease is hepatocellular carcinoma.